Bevacizumab biosimilars Mvasi and Zirabev provided cost savings for metastatic colorectal cancer (mCRC) treatment without compromising effectiveness.
A real-world, economic evaluation based on a population-based retrospective cohort study in Ontario, Canada, found that prescribing bevacizumab biosimilars Mvasi and Zirabev as first-line treatments for patients with metastatic colorectal cancer (mCRC) provided cost savings with no differences in life years or quality-adjusted life years (QALYs) compared with the originator (Avastin).
A real-world economic evaluation in Ontario, Canada, found that first-line treatment of metastatic colorectal cancer (mCRC) with bevacizumab biosimilars Mvasi and Zirabev provided significant cost savings without compromising life years or quality-adjusted life years (QALYs) compared with the originator Avastin. | Image credit: Sebastian Kaulitzki - stock.adobe.com
The researchers said the 2 biosimilars were cost-effective “at all conventional willingness-to-pay thresholds, indicating the importance and value of biosimilars for improved health system sustainability.” The real-world, 1-year cost savings associated with the use of one of these biosimilars for 1 patient was $6379 CAD.
The authors noted that the economic burden of cancer treatment is growing, largely driven by the costs of biologic drugs, such as bevacizumab, an antibody targeting vascular endothelial growth factor, an inducer of angiogenesis. Mvasi (Amgen) and Zirabev (Pfizer) are bevacizumab biosimilars approved for first-line treatment of mCRC in the US, Europe, and Canada. Since their approvals for mCRC were based on extrapolation from randomized controlled trials in non-small cell lung cancer, the authors wrote, “there is a paucity of indication-specific randomized-controlled trial and real-world evidence for the use of bevacizumab biosimilars in the first-line setting of mCRC.” Furthermore, they cited previous economic evaluations from several countries that have suggested the bevacizumab reference product is not a cost-effective treatment for mCRC at list prices.
Patients with mCRC in Ontario who received one of the biosimilars (n = 742) were matched 1:4 to patients who received the reference product (n = 2945). Of patients who were treated with biosimilars, 635 (86%) received Mvasi and 112 (15%) received Zirabev.
First-line treatment of mCRC with a bevacizumab biosimilar was associated with a 1-year patient-level cost savings of $6379 CAD (95% CI, $3537-$9417), with a mean total cost of $84,162 for a biosimilar compared to $90,541 for the reference bevacizumab. Mean life years and QALYs were not significantly different between the biosimilar and originator groups.
Incremental net monetary benefit was estimated at $6331 (95% CI, 6245-6417) and incremental net health benefit (INHB) was estimated at 0.127 life years (95% CI, 0.125-0.128) at a willingness-to-pay threshold of $50,000 per life year gained. The authors added that INMB and INHB estimates also indicated cost-effectiveness of the biosimilars compared to the reference product at willingness-to-pay thresholds of $100,000, $150,000, and $200,000 per life year gained. Subgroup analyses by biosimilar product and 2-year analyses suggested “consistent” cost-effectiveness.
The authors said their study confirms the benefits and cost-savings possible with bevacizumab biosimilars in mCRC and justifies Ontario’s policy to mandate the use of biosimilars for treating mCRC. They said their study can inform future policy decisions elsewhere in Canada and in other regions around the funding of bevacizumab biosimilars. “Decision makers can rely on the evidence of cost savings achieved through the use of biosimilars and be confident in the role they play in improving the efficiency and sustainability of the healthcare system,” they wrote.
Reference
Lu B, Dvorani E, Nguyen L, Beca JM, Mercer RE, Adamic A, Muñoz C, Chan KKW. Cost-effectiveness analysis of bevacizumab biosimilars versus originator bevacizumab for metastatic colorectal cancer: a comparative study using real-world data. Value Health. 2024;27(12):1689-1697. doi:10.1016/j.jval.2024.07.018
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Similar Survival, Safety for Bevacizumab Biosimilar vs Originator in Colorectal Cancer
February 8th 2025A retrospective observational study found no significant differences in progression-free survival or safety in patients with colorectal cancers in Japan treated with ABP 215, Amgen’s bevacizumab biosimilar, or reference bevacizumab (Avastin), and estimated cost savings of 800,000 Japanese yen (approximately $5100) per patient with the biosimilar.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
A Banner Year for Biosimilars: The 19 FDA Approvals From 2024
January 21st 2025In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab and denosumab, marking significant progress in expanding treatment options and market competition.